131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
Running, not enrolling · Phase 2
Conditions studied: Recurrent Medulloblastoma, Recurrent Ependymoma
In brief
A Phase 2 study investigating the addition of cRIT 131I-omburtamab to irinotecan, temozolomide, and bevacizumab for patients with recurrent medulloblastoma. A feasibility cohort is included to assess the feasibility of incorporating cRIT 131I-omburtamab for patients with recurrent ependymoma. Direct intraventricular delivery of radiolabeled tumor-specific antibodies may aid in both the detection and treatment of recurrent disease for these highly specific pediatric patients with recurrent tumors.
Key facts
- Study ID
- NCT04743661
- Run by
- Pediatric Brain Tumor Consortium
- People needed
- 62
- Starts
- 2022-04-04
- Expected to finish
- 2027-09-30
- Last updated by the study team
- 2026-07-28
Who can join
Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Children's Hospital Los Angeles — Los Angeles, California, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.